首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

2096352

全球生物標記市場（至2031年）：依產品類別、類型、研究領域、技術、疾病及應用分類

Biomarkers Market by Offering, Type, Research Area, Technology, Disease, Application - Global Forecast to 2031

出版日期: 2026年07月03日 | 出版商:

MarketsandMarkets | 英文 732 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球生物標記市場預計將從 2026 年的 679.5 億美元成長到 2031 年的 1,121 億美元，2026 年至 2031 年的複合年成長率為 10.5%。

這一成長是由人工智慧、數位病理學和生物資訊學的日益融合，以及精準醫療和伴隨診斷的不斷普及所推動的。

調查範圍
調查期	2026-2031
基準年	2025
預測期	2026-2031
單元	金額（美元）
部分	類別、類型、研究領域、技術、適應症、應用、最終用戶
目標區域	北美洲、歐洲、亞太地區、拉丁美洲、中東、非洲

到 2025 年，預測性生物標記細分市場將佔據療效生物標記市場的最大佔有率。

生物標記市場分為三大類：安全性生物標記、療效生物標記和驗證性生物標記。療效生物標記進一步細分為預測性生物標記、替代性生物標記、動態標記和預後生物標記。 2024年，預測性生物標記在全球療效生物標記市場佔有率中佔據最大佔有率。這主要是因為預測性生物標記在識別最有可能對特定治療產生反應的患者方面發揮著至關重要的作用，從而實現個別化治療。這項功能最終有助於改善治療效果並促進更精準的臨床決策。

預測性生物標記的應用在腫瘤學、自體免疫疾病和感染疾病等領域正迅速發展。此外，針對預測性生物標記的伴隨診斷產品核准數量的不斷增加也推動了市場應用。例如，2026年6月，FDA批准了羅氏公司首個用於評估前列腺癌中PTEN蛋白的伴隨診斷產品。 VENTANA PTEN檢測能夠辨識出適合接受更精準治療的患者。

按技術分類，預計到 2025 年，免疫測量技術將在生物標記市場中佔據最大佔有率。

生物標記市場依技術分類，包括免疫測量、次世代定序(NGS)、聚合酵素鏈鎖反應(PCR)、質譜和層析法。預計到 2025 年，免疫測量將佔據生物標記市場最大的佔有率，這主要歸功於其高特異性和檢測多種疾病領域（尤其是循環系統疾病和感染疾病）多種生物標記的能力。

免疫測量因其適用於臨床診斷和研究應用，是生物標記檢測的首選方法。此外，其擴充性和自動化能力使其能夠進行高通量檢測，這對於滿足日益成長的精準診斷需求至關重要。

領先企業正積極改進免疫測量平台，以提升診斷產品和服務。例如，羅氏公司提供用於癌症診斷的Elecsys Anti-p53免疫測量盒。同時，雅培公司正在拓展其ARCHITECT和Alinity免疫測量系統的應用範圍，以支持傳染病檢查和慢性病監測。

從 2026 年到 2031 年，亞太地區將是成長最快的區域市場。

預計亞太地區在預測期內將錄得最高的複合年成長率。這一成長主要得益於中國、印度和日本等國家醫療衛生基礎設施的持續改善，以及對精準醫療、基因組研究和診斷技術創新領域投資的增加。

癌症、心血管疾病、代謝紊亂和感染疾病等慢性疾病的日益流行，正在加速推動對基於生物標記的診斷和個人化治療的需求。此外，臨床試驗活動的擴展、伴隨診斷的普及、政府對生物技術和生命科學研究的支持，以及基因組學、蛋白質組學和人工智慧分析技術的快速整合，都促進了該地區市場的成長。

此外，隨著本地生物製藥生產能力的擴大和法規結構的完善，商業化機會正在增加，亞太地區正在成為生物標記市場成長和創新的關鍵中心。

公司簡介列表：

F. Hoffmann-La Roche Ltd.（瑞士）
默克集團（德國）
雅培（美國）
Thermo Frequency Scientific, Inc.（美國）
凱傑（德國）
查爾斯河實驗室（美國）
Eurofins Scientific（盧森堡）
LabCorp（美）
Revvity（美國）
生物梅里埃（法國）
Guardant Health（美國）
JSR株式會社（皇冠生物科學）（日本）
安捷倫科技公司（美國）
Bio-Rad Laboratories（美國）
Illumina公司（美國）
Quanterix（美國）
Meso Scale Diagnostics, LLC（美國）
IntertekGroup Limited（英國）
Meridian Bioscience（美國）
BioAgilytix Labs（美國）
R-Biopharm AG（德國）
Enzo Biochem（美國）
藥明康德（中國）
Standard BioTools（美國）
Diatech Pharmacogenetics（義大利）
Synexa Life Sciences BV（荷蘭）
蛋白質體科學（英國）
Pillar Biosciences（美國）
StressMarq Biosciences Inc.（加拿大）
塞比亞（法國）
Bio-Techne（美國）
C2N 非那雄胺（美國）
東北生物分析實驗室（美國）
Signosis（美國）
Myriad Genetics, Inc.（美國）

本報告考察了全球生物標記市場，提供了概述、影響市場成長的各種因素分析、技術和專利趨勢、法律制度、案例研究、歷史和預測市場規模、按細分市場、地區/主要國家/地區進行的詳細分析、競爭格局以及主要公司的概況。

簡介目錄圖表

Product Code: BT 2120

The global biomarkers market is expected to reach USD 112.10 billion by 2031 from USD 67.95 billion in 2026, at a CAGR of 10.5% from 2026 to 2031. This growth is driven by the increasing integration of artificial intelligence, digital pathology, and bioinformatics, as well as the rising adoption of precision medicine and companion diagnostics.

Scope of the Report
Years Considered for the Study	2026-2031
Base Year	2025
Forecast Period	2026-2031
Units Considered	Value (USD billion)
Segments	Offering, Type, Research Area, Technology, Disease Indication, Application, and End User
Regions covered	North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

In 2025, the predictive biomarkers segment accounted for the largest share of the efficacy biomarkers market.

The biomarkers market is categorized by type into three segments: safety, efficacy, and validation biomarkers. The efficacy biomarkers segment is further divided into predictive, surrogate, pharmacodynamic, and prognostic biomarkers. In 2024, predictive biomarkers accounted for the largest share globally in the efficacy biomarkers segment. This dominance is primarily due to their crucial role in facilitating personalized treatment by identifying patients most likely to respond to specific therapies. This capability ultimately improves treatment outcomes and enhances clinical decision-making.

The use of predictive biomarkers has gained significant traction in fields such as oncology, autoimmune diseases, and infectious diseases. Additionally, the increasing number of companion diagnostic approvals for predictive biomarkers is driving market adoption. For instance, in June 2026, the FDA approved Roche's first companion diagnostic to assess the PTEN protein in prostate cancer. The VENTANA PTEN assay enables the identification of patients eligible for more targeted treatment decisions.

By technology, the immunoassays segment held the largest share of the biomarkers market in 2025.

The biomarkers market is divided into several technologies, including immunoassays, NGS (next-generation sequencing), PCR (polymerase chain reaction), mass spectrometry, chromatography, and others. In 2025, immunoassays are expected to hold the largest share of the biomarker market due to their high specificity and ability to detect a wide range of biomarkers across various disease areas, particularly in oncology, cardiology, and infectious diseases.

Immunoassays are favored for biomarker detection because they are compatible with both clinical diagnostics and research applications. Additionally, their scalability and automation capabilities enable high-throughput testing, which is essential for meeting the increasing demand for precision diagnostics.

Major companies are actively enhancing their immunoassay platforms to improve their diagnostic offerings. For instance, Roche provides the Elecsys Anti-p53 immunoassay for cancer diagnostics, while Abbott is expanding its ARCHITECT and Alinity immunoassay systems to test for infectious diseases and monitor chronic conditions.

APAC is the fastest-growing regional segment in the global biomarkers market from 2026 to 2031.

The biomarkers market is divided into several regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to experience the highest CAGR during the forecast period. This growth is primarily driven by the expanding healthcare infrastructure in countries such as China, India, and Japan, along with increasing investments in precision medicine, genomic research, and diagnostic innovation.

The rising prevalence of chronic diseases, including cancer, cardiovascular disorders, metabolic diseases, and infectious diseases, is accelerating the demand for biomarker-based diagnostics and personalized treatment approaches. Additionally, the growth of clinical trial activities, the increasing adoption of companion diagnostics, supportive government initiatives for biotechnology and life sciences research, and the rapid integration of genomics, proteomics, and AI-enabled analytics are all contributing to the regional market growth.

Furthermore, expanding local biopharmaceutical manufacturing capabilities and improving regulatory frameworks are enhancing commercialization opportunities, establishing the Asia Pacific region as a significant hub for growth and innovation in the biomarkers market.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side (70%) and Demand Side (30%)
By Designation: Managers (45%), CXO and Directors (30%), and Executives (25%)
By Region: North America (40%), Europe (25%), the Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

List of Companies Profiled in the Report

F. Hoffmann-La Roche Ltd. (Switzerland)
Merck KGaA (Germany)
Abbott (US)
Thermo Fisher Scientific, Inc. (US)
QIAGEN (Germany)
Charles River Laboratories (US)
Eurofins Scientific (Luxembourg)
LabCorp (US)
Revvity (US)
bioMerieux (France)
Guardant Health (US)
JSR Corporation (Crown Biosciences) (Japan)
Agilent Technologies, Inc. (US)
Bio-Rad Laboratories (US)
Illumina, Inc. (US)
Quanterix (US)
Meso Scale Diagnostics, LLC (US)
Intertek Group Plc (UK)
Meridian Bioscience (US)
BioAgilytix Labs (US)
R-Biopharm AG (Germany)
Enzo Biochem (US)
WuXi AppTec (China)
Standard BioTools (US)
Diatech Pharmacogenetics (Italy)
Synexa Life Sciences BV (Netherlands)
Proteome Sciences (UK)
Pillar Biosciences (US)
StressMarq Biosciences Inc. (Canada)
Sebia (France)
Bio-Techne (US)
C2N Diagnostics (US)
NorthEast Bioanalytical Laboratories (US)
Signosis (US)
Myriad Genetics, Inc. (US)

Research Coverage:

This research report categorizes the global biomarkers market by offering, type, research area, technology, disease indication, and end user.

The report provides comprehensive information about the key factors influencing the growth of the biomarkers market, including drivers, restraints, challenges, and opportunities. It also includes a detailed analysis of major industry players, offering insights into their business overviews, products, solutions, key strategies, collaborations, partnerships, and agreements. Additionally, the report covers new approvals and product launches, as well as recent collaborations, acquisitions, and developments within the global biomarkers market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of revenue numbers for the overall biomarkers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (rising adoption of precision medicine and companion diagnostics, growing use of NGS, PCR, proteomics, and multi-omics platforms, increasing biomarker use in drug discovery and clinical trial design, rising burden of cancer, cardiovascular, neurological, and infectious diseases, expansion of liquid biopsy and minimally invasive biomarker testing, and increasing integration of AI, digital pathology, and bioinformatics), restraints (high cost of advanced biomarker discovery and validation and complex regulatory and reimbursement pathways), opportunities (co-development of biomarkers with targeted therapies and immunotherapies, expansion of blood-based biomarkers for oncology and neurology, growth in proteomics, spatial biology, and multi-omics biomarker discovery, and rising outsourcing of biomarker assay development and validation), and challenges (translating discovery biomarkers into clinically validated tests and patient heterogeneity and disease complexity)
Product Development/Innovation: Detailed insights on upcoming technologies and research & development activities in the global biomarkers market
Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the global biomarkers market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been conducted to provide insights into their strategies, product launches/approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics for the global biomarkers market.

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

3.1 BIOMARKERS MARKET OVERVIEW
3.2 BIOMARKERS MARKET, BY TYPE & REGION
3.3 BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT

4 MARKET OVERVIEW

4.1 INTRODUCTION
4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
  - 4.2.1.1 Rising adoption of precision medicine and companion diagnostics
  - 4.2.1.2 Growing use of NGS, PCR, proteomics, and multi-omics platforms
  - 4.2.1.3 Increasing biomarker use in drug discovery and clinical trial design
  - 4.2.1.4 Rising burden of cancer, cardiovascular, neurological, and infectious diseases
  - 4.2.1.5 Expansion of liquid biopsy and minimally invasive biomarker testing
  - 4.2.1.6 Increasing integration of AI, digital pathology, and bioinformatics
- 4.2.2 RESTRAINTS
  - 4.2.2.1 High cost of advanced biomarker discovery and validation
  - 4.2.2.2 Complex regulatory and reimbursement pathways

4.2.3 OPPORTUNITIES

4.2.3.1 Co-development of biomarkers with targeted therapies and immunotherapies
4.2.3.2 Expansion of blood-based biomarkers for oncology and neurology
4.2.3.3 Growth in proteomics, spatial biology, and multi-omics biomarker discovery
4.2.3.4 Rising outsourcing of biomarker assay development and validation

4.2.4 CHALLENGES
- 4.2.4.1 Patient heterogeneity and disease complexity
- 4.2.4.2 Translating discovery biomarkers into clinically validated tests

4.3 UNMET NEEDS & WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 THREAT OF SUBSTITUTES
- 5.1.3 BARGAINING POWER OF BUYERS
- 5.1.4 BARGAINING POWER OF SUPPLIERS
- 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS & FORECAST
- 5.2.3 TRENDS IN GLOBAL BIOMARKERS MARKET
5.3 SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.6 PRICING ANALYSIS
- 5.6.1 AVERAGE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023-2025
- 5.6.2 INDICATIVE SELLING PRICE OF CONSUMABLES, BY REGION, 2025
5.7 TRADE ANALYSIS
- 5.7.1 IMPORT DATA
- 5.7.2 EXPORT DATA
- 5.7.3 IMPORT VOLUME
- 5.7.4 EXPORT VOLUME
5.8 KEY CONFERENCES & EVENTS, 2026-2027
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.10 INVESTMENT/FUNDING ACTIVITY
5.11 CASE STUDY ANALYSIS
5.12 IMPACT OF 2025 US TARIFFS ON BIOMARKERS MARKET
- 5.12.1 INTRODUCTION
- 5.12.2 KEY TARIFF RATES
- 5.12.3 PRICE IMPACT ANALYSIS
- 5.12.4 IMPACT ON COUNTRY/REGION
  - 5.12.4.1 North America
  - 5.12.4.2 Europe
  - 5.12.4.3 Asia Pacific
- 5.12.5 IMPACT ON END-USE INDUSTRIES
  - 5.12.5.1 Pharmaceutical & biotechnology companies
  - 5.12.5.2 Hospitals & diagnostic laboratories
  - 5.12.5.3 Academic & research institutes
  - 5.12.5.4 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

6.1 TECHNOLOGY ANALYSIS
- 6.1.1 KEY TECHNOLOGIES
  - 6.1.1.1 Immunoassays
  - 6.1.1.2 Next-generation sequencing (NGS)
  - 6.1.1.3 Polymerase chain reaction (PCR)
  - 6.1.1.4 In situ hybridization
  - 6.1.1.5 Microarrays
  - 6.1.1.6 Mass spectrometry
- 6.1.2 ADJACENT TECHNOLOGIES
  - 6.1.2.1 Artificial intelligence (AI) and machine learning (ML)
  - 6.1.2.2 Sensors (wearable devices)
- 6.1.3 COMPLEMENTARY TECHNOLOGIES
  - 6.1.3.1 Liquid biopsy
  - 6.1.3.2 CRISPR
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.3 PATENT ANALYSIS
- 6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOMARKER PATENTS, 2015-2025
6.4 FUTURE APPLICATIONS
6.5 IMPACT OF AI/GEN AI ON BIOMARKERS MARKET
- 6.5.1 TOP USE CASES & MARKET POTENTIAL
- 6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN BIOMARKERS MARKET
- 6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
- 6.5.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN BIOMARKERS MARKET
6.6 SUCCESS STORIES & REAL-WORLD APPLICATIONS

7 SUSTAINABILITY & REGULATORY LANDSCAPE

7.1 REGIONAL REGULATIONS & COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.2 REGULATORY FRAMEWORK
- 7.1.3 INDUSTRY STANDARDS
7.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY

9 BIOMARKERS MARKET, BY OFFERING

9.1 INTRODUCTION
9.2 CONSUMABLES
- 9.2.1 ASSAY KITS
  - 9.2.1.1 Growing demand for assay kits in biomarker detection, quantification, and characterization to support growth
- 9.2.2 REAGENTS & CHEMICALS
  - 9.2.2.1 Recurrent usage of reagents & chemicals in drug discovery and development to support demand
- 9.2.3 OTHER CONSUMABLES
9.3 SERVICES
- 9.3.1 GRADUAL TRANSITION FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING SERVICES TO FUEL MARKET EXPANSION
9.4 SOFTWARE
- 9.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO DRIVE MARKET GROWTH

10 BIOMARKERS MARKET, BY TYPE

10.1 INTRODUCTION
10.2 SAFETY BIOMARKERS
- 10.2.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN THERAPEUTIC AREAS & DEVELOPMENT TO BOOST MARKET GROWTH
10.3 EFFICACY BIOMARKERS
- 10.3.1 PREDICTIVE BIOMARKERS
  - 10.3.1.1 Rising applications of biomarkers in personalized medicine to drive market
- 10.3.2 SURROGATE BIOMARKERS
  - 10.3.2.1 Ability to serve as reliable indicators in place of clinical endpoints to support market growth
- 10.3.3 PHARMACODYNAMIC BIOMARKERS
  - 10.3.3.1 Increasing utilization of pharmacodynamic biomarkers in biomarker and drug development to boost market
- 10.3.4 PROGNOSTIC BIOMARKERS
  - 10.3.4.1 Increasing number of clinical trials to support growth of prognostic biomarkers
10.4 VALIDATION BIOMARKERS
- 10.4.1 RISING RESEARCH FOR NEW DRUG DISCOVERY & DEVELOPMENT TO BOOST MARKET GROWTH

11 BIOMARKERS MARKET, BY RESEARCH AREA

11.1 INTRODUCTION
11.2 GENOMICS
- 11.2.1 ADVANCEMENTS IN GENOMICS TECHNOLOGIES TO DRIVE SEGMENT GROWTH
11.3 PROTEOMICS
- 11.3.1 GROWING PATIENT POPULATION WITH CHRONIC DISEASES TO DRIVE DEMAND
11.4 METABOLOMICS
- 11.4.1 RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH
11.5 OTHER RESEARCH AREAS

12 BIOMARKERS MARKET, BY TECHNOLOGY

12.1 INTRODUCTION
12.2 IMMUNOASSAYS
- 12.2.1 ELISA
  - 12.2.1.1 Extensive application of ELISA assays in clinical laboratories to support growth
- 12.2.2 PROTEIN MICROARRAYS
  - 12.2.2.1 Quick and cost-effective nature of technology to support growth
- 12.2.3 WESTERN BLOT
  - 12.2.3.1 Increasing investments in proteomics research to drive market
12.3 NEXT-GENERATION SEQUENCING (NGS)
- 12.3.1 TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO SUPPORT GROWTH
12.4 POLYMERASE CHAIN REACTION (PCR)
- 12.4.1 RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET
12.5 MASS SPECTROMETRY
- 12.5.1 INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE GROWTH

12.6 CHROMATOGRAPHY

12.6.1 GROWING UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH

12.7 OTHER TECHNOLOGIES

13 BIOMARKERS MARKET, BY APPLICATION

13.1 INTRODUCTION
13.2 CLINICAL DIAGNOSTICS
- 13.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO SUPPORT DEMAND
13.3 DRUG DISCOVERY & DEVELOPMENT
- 13.3.1 INCREASING UTILIZATION OF BIOMARKERS IN DRUG DEVELOPMENT TO SUPPORT GROWTH
13.4 PERSONALIZED MEDICINE
- 13.4.1 GROWING PREFERENCE FOR PRECISION THERAPEUTICS TO SUPPORT DEMAND
13.5 CLINICAL RESEARCH
- 13.5.1 GROWING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET
13.6 OTHER APPLICATIONS

14 BIOMARKERS MARKET, BY DISEASE INDICATION

14.1 INTRODUCTION
14.2 CANCER
- 14.2.1 BREAST CANCER
  - 14.2.1.1 Expanding precision oncology and companion diagnostics to drive global growth in breast cancer biomarkers
- 14.2.2 LUNG CANCER
  - 14.2.2.1 Expanding targeted therapies and rapid molecular profiling to drive global growth in lung cancer biomarkers
- 14.2.3 COLORECTAL CANCER
  - 14.2.3.1 Expanding RAS/BRAF testing, liquid biopsy, and biomarker-linked targeted therapies to drive global
- 14.2.4 PROSTATE CANCER
  - 14.2.4.1 Growth in HRR, PTEN, and liquid biopsy testing to accelerate biomarker adoption
- 14.2.5 HEMATOLOGICAL CANCER
  - 14.2.5.1 Rising MRD monitoring and targeted hematology therapies to drive global growth in hematological cancer biomarkers
- 14.2.6 OTHER CANCERS
14.3 INFECTIOUS DISEASES
- 14.3.1 HIV/AIDS
  - 14.3.1.1 Expanding self-testing and viral load monitoring to drive global growth

14.3.2 HEPATITIS (B & C)

14.3.2.1 Rising hepatitis screening and automated immunoassay adoption to drive growth of HBV and HCV biomarkers

14.3.3 RESPIRATORY INFECTIONS
- 14.3.3.1 Rising MRD monitoring and targeted hematology therapies to drive global growth in hematological cancer biomarkers
14.3.4 OTHER INFECTIOUS DISEASES

14.4 IMMUNOLOGICAL DISORDERS
- 14.4.1 RHEUMATOID ARTHRITIS
  - 14.4.1.1 Earlier diagnosis and therapy-response stratification to drive growth in rheumatoid arthritis biomarkers
- 14.4.2 INFLAMMATORY BOWEL DISEASE
  - 14.4.2.1 Non-invasive inflammation monitoring and targeted therapy management to drive growth in IBD biomarkers
- 14.4.3 OTHER IMMUNOLOGICAL DISORDERS
14.5 NEUROLOGICAL DISORDERS
- 14.5.1 ALZHEIMER'S DISEASE
  - 14.5.1.1 Growing demand for less-invasive alternatives to PET imaging and cerebrospinal fluid testing to boost market growth
- 14.5.2 PARKINSON'S DISEASE
  - 14.5.2.1 Alpha-synuclein and digital biomarker advances to drive growth in Parkinson's disease biomarkers
- 14.5.3 MULTIPLE SCLEROSIS
  - 14.5.3.1 Blood-based neurofilament light chain testing to strengthen growth in multiple sclerosis biomarkers
- 14.5.4 OTHER NEUROLOGICAL DISORDERS
14.6 METABOLIC & ENDOCRINE DISORDERS
- 14.6.1 DIABETES
  - 14.6.1.1 Continuous glucose-ketone monitoring and connected diabetes care to drive growth in diabetes biomarkers
- 14.6.2 OBESITY
  - 14.6.2.1 GLP-1 therapy expansion and payer demand for response prediction to drive growth in obesity biomarkers
- 14.6.3 OTHER METABOLIC & ENDOCRINE DISORDERS
14.7 CARDIOVASCULAR DISORDERS
- 14.7.1 CONTINUOUS INNOVATION IN CARDIAC BIOMARKERS TO BOOST MARKET GROWTH
14.8 OTHER DISEASE INDICATIONS

15 BIOMARKERS MARKET, BY END USER

15.1 INTRODUCTION
15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 15.2.1 GROWING MARKET STRATEGIES BY KEY PLAYERS TO SUPPORT MARKET GROWTH

15.3 HOSPITALS & DIAGNOSTIC LABORATORIES

15.3.1 VITAL ROLE OF BIOMARKERS AS BIOLOGICAL INDICATORS IN DIAGNOSIS OF DISEASES TO FUEL MARKET GROWTH

15.4 ACADEMIC & RESEARCH INSTITUTES
- 15.4.1 INCREASING FUNDING ACTIVITIES TO DRIVE MARKET
15.5 OTHER END USERS

16 BIOMARKERS MARKET, BY REGION

16.1 INTRODUCTION
16.2 NORTH AMERICA
- 16.2.1 US
  - 16.2.1.1 Rising focus on biopharma research to support growth
- 16.2.2 CANADA
  - 16.2.2.1 Increasing incidence of cancer to drive biomarkers market growth
16.3 EUROPE
- 16.3.1 GERMANY
  - 16.3.1.1 Growth in biopharmaceutical R&D activities to propel growth
- 16.3.2 UK
  - 16.3.2.1 Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers
- 16.3.3 FRANCE
  - 16.3.3.1 Increasing government investment for proteomics & genomics research to drive growth
- 16.3.4 ITALY
  - 16.3.4.1 Increasing developments in life science research to fuel growth
- 16.3.5 SPAIN
  - 16.3.5.1 R&D initiatives for personalized medicine to support market growth
- 16.3.6 REST OF EUROPE
16.4 ASIA PACIFIC
- 16.4.1 CHINA
  - 16.4.1.1 Rising incidence of CVD to propel market
- 16.4.2 JAPAN
  - 16.4.2.1 Strong regulatory guidelines for drug discovery & development to support market growth
- 16.4.3 INDIA
  - 16.4.3.1 Favorable scenario for FDI and increasing number of clinical trials to propel market
- 16.4.4 SOUTH KOREA
  - 16.4.4.1 Increasing innovations in NGS technologies to support market growth
- 16.4.5 AUSTRALIA
  - 16.4.5.1 Increasing demand for diagnostic solutions to propel market
- 16.4.6 REST OF ASIA PACIFIC

16.5 LATIN AMERICA

16.5.1 BRAZIL
- 16.5.1.1 Increased government investments in pharmaceutical R&D to drive market
16.5.2 MEXICO
- 16.5.2.1 Rising demand for chronic disease treatment to support market growth
16.5.3 REST OF LATIN AMERICA

16.6 MIDDLE EAST
- 16.6.1 GCC COUNTRIES
  - 16.6.1.1 Saudi Arabia
    - 16.6.1.1.1 Growing healthcare expenditure to boost market growth
  - 16.6.1.2 UAE
    - 16.6.1.2.1 Increasing collaborative efforts for pharmaceutical R&D to drive growth
  - 16.6.1.3 Rest of GCC countries
- 16.6.2 REST OF MIDDLE EAST
16.7 AFRICA
- 16.7.1 INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET

17 COMPETITIVE LANDSCAPE

17.1 OVERVIEW
17.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET, 2023-2026
17.3 REVENUE ANALYSIS, 2023-2025
17.4 MARKET SHARE ANALYSIS, 2025
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 17.5.1 STARS
- 17.5.2 EMERGING LEADERS
- 17.5.3 PERVASIVE PLAYERS
- 17.5.4 PARTICIPANTS
- 17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
  - 17.5.5.1 Company footprint
  - 17.5.5.2 Region footprint
  - 17.5.5.3 Offering footprint
  - 17.5.5.4 Technology footprint
  - 17.5.5.5 Application footprint
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 17.6.1 PROGRESSIVE COMPANIES
- 17.6.2 RESPONSIVE COMPANIES
- 17.6.3 DYNAMIC COMPANIES
- 17.6.4 STARTING BLOCKS
- 17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
  - 17.6.5.1 Detailed list of key startups/SME players
  - 17.6.5.2 Competitive benchmarking of key startups/SME players
17.7 COMPANY VALUATION & FINANCIAL METRICS
- 17.7.1 FINANCIAL METRICS
- 17.7.2 COMPANY VALUATION
17.8 BRAND/PRODUCT COMPARISON
17.9 COMPETITIVE SCENARIO
- 17.9.1 PRODUCT LAUNCHES & APPROVALS
- 17.9.2 DEALS
- 17.9.3 EXPANSIONS

18 COMPANY PROFILES

18.1 KEY PLAYERS
- 18.1.1 F. HOFFMANN-LA ROCHE LTD.
  - 18.1.1.1 Business overview
  - 18.1.1.2 Products & services offered
  - 18.1.1.3 Recent developments
    - 18.1.1.3.1 Product launches & approvals
    - 18.1.1.3.2 Deals
  - 18.1.1.4 MnM view
    - 18.1.1.4.1 Right to win
    - 18.1.1.4.2 Strategic choices
    - 18.1.1.4.3 Weaknesses & competitive threats
- 18.1.2 DANAHER CORPORATION
  - 18.1.2.1 Business overview
  - 18.1.2.2 Products offered
  - 18.1.2.3 MnM view
    - 18.1.2.3.1 Right to win
    - 18.1.2.3.2 Strategic choices
    - 18.1.2.3.3 Weaknesses & competitive threats
- 18.1.3 ILLUMINA, INC.
  - 18.1.3.1 Business overview
  - 18.1.3.2 Products & services offered
  - 18.1.3.3 Recent developments
    - 18.1.3.3.1 Product launches & approvals
    - 18.1.3.3.2 Deals
  - 18.1.3.4 MnM view
    - 18.1.3.4.1 Right to win
    - 18.1.3.4.2 Strategic choices
    - 18.1.3.4.3 Weaknesses & competitive threats

18.1.4 MERCK KGAA

18.1.4.1 Business overview
18.1.4.2 Products & services offered
18.1.4.3 Recent developments
- 18.1.4.3.1 Deals
- 18.1.4.3.2 Expansions
18.1.4.4 MnM view
- 18.1.4.4.1 Right to win
- 18.1.4.4.2 Strategic choices
- 18.1.4.4.3 Weaknesses & competitive threats

18.1.5 THERMO FISHER SCIENTIFIC INC.
- 18.1.5.1 Business overview
- 18.1.5.2 Products & services offered
- 18.1.5.3 Recent developments
  - 18.1.5.3.1 Product approvals
  - 18.1.5.3.2 Deals
  - 18.1.5.3.3 Expansions
- 18.1.5.4 MnM view
  - 18.1.5.4.1 Right to win
  - 18.1.5.4.2 Strategic choices
  - 18.1.5.4.3 Weaknesses & competitive threats
18.1.6 QIAGEN
- 18.1.6.1 Business overview
- 18.1.6.2 Products & services offered
- 18.1.6.3 Recent developments
  - 18.1.6.3.1 Product launches
  - 18.1.6.3.2 Deals
  - 18.1.6.3.3 Expansions
18.1.7 ABBOTT
- 18.1.7.1 Business overview
- 18.1.7.2 Products & services offered
- 18.1.7.3 Recent developments
  - 18.1.7.3.1 Product approvals
  - 18.1.7.3.2 Deals
18.1.8 AGILENT TECHNOLOGIES, INC.
- 18.1.8.1 Business overview
- 18.1.8.2 Products & services offered
- 18.1.8.3 Recent developments
  - 18.1.8.3.1 Product approvals
  - 18.1.8.3.2 Deals

18.1.9 REVVITY INC.

18.1.9.1 Business overview
18.1.9.2 Products & services offered
18.1.9.3 Recent developments
- 18.1.9.3.1 Product launches

18.1.10 CHARLES RIVER LABORATORIES
- 18.1.10.1 Business overview
- 18.1.10.2 Products & services offered
- 18.1.10.3 Recent developments
  - 18.1.10.3.1 Deals
18.1.11 BIO-RAD LABORATORIES, INC.
- 18.1.11.1 Business overview
- 18.1.11.2 Products & services offered
- 18.1.11.3 Recent developments
  - 18.1.11.3.1 Product launches
  - 18.1.11.3.2 Deals
18.1.12 EUROFINS SCIENTIFIC
- 18.1.12.1 Business overview
- 18.1.12.2 Products & services offered
- 18.1.12.3 Recent developments
  - 18.1.12.3.1 Deals
18.1.13 BIOMERIEUX
- 18.1.13.1 Business overview
- 18.1.13.2 Products & services offered
- 18.1.13.3 Recent developments
  - 18.1.13.3.1 Product approvals
  - 18.1.13.3.2 Deals
  - 18.1.13.3.3 Expansions
18.1.14 JSR CORPORATION
- 18.1.14.1 Business overview
- 18.1.14.2 Products & services offered
- 18.1.14.3 Recent developments
  - 18.1.14.3.1 Deals
18.1.15 GUARDANT HEALTH
- 18.1.15.1 Business overview
- 18.1.15.2 Products & services offered
- 18.1.15.3 Recent developments
  - 18.1.15.3.1 Product approvals
  - 18.1.15.3.2 Deals
18.1.16 LABCORP
- 18.1.16.1 Business overview
- 18.1.16.2 Products & services offered
- 18.1.16.3 Recent developments
  - 18.1.16.3.1 Product launches
18.1.17 QUANTERIX
- 18.1.17.1 Business overview
- 18.1.17.2 Products & services offered
- 18.1.17.3 Recent developments
  - 18.1.17.3.1 Product launches
  - 18.1.17.3.2 Deals
18.1.18 MESO SCALE DIAGNOSTICS, LLC
- 18.1.18.1 Business overview
- 18.1.18.2 Products & services offered
18.1.19 SIEMENS HEALTHINEERS AG
- 18.1.19.1 Business overview
- 18.1.19.2 Products offered

18.2 OTHER PLAYERS
- 18.2.1 CELERION
- 18.2.2 STANDARD BIOTOOLS
- 18.2.3 SEBIA
- 18.2.4 BIOAGILYTIX LABS
- 18.2.5 STRESSMARQ BIOSCIENCES INC.
- 18.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC
- 18.2.7 SIGNOSIS
- 18.2.8 SERIMMUNE
- 18.2.9 THERAINDX LIFESCIENCES PVT. LTD.
- 18.2.10 SYNEXA LIFE SCIENCES BV
- 18.2.11 DIATECH PHARMACOGENETICS
- 18.2.12 PILLAR BIOSCIENCES
- 18.2.13 R-BIOPHARM AG

19 RESEARCH METHODOLOGY

19.1 RESEARCH DATA
- 19.1.1 SECONDARY DATA
- 19.1.2 PRIMARY DATA
19.2 MARKET ESTIMATION METHODOLOGY
- 19.2.1 INSIGHTS OF PRIMARY EXPERTS
- 19.2.2 TOP-DOWN APPROACH
19.3 MARKET GROWTH RATE FORECAST
19.4 MARKET BREAKDOWN & DATA TRIANGULATION
19.5 RESEARCH ASSUMPTIONS
19.6 RESEARCH LIMITATIONS
19.7 RISK ASSESSMENT

20 APPENDIX

20.1 DISCUSSION GUIDE
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
20.3 CUSTOMIZATION OPTIONS
20.4 RELATED REPORTS
20.5 AUTHOR DETAILS

簡介目錄圖表

List of Tables

TABLE 1 BIOMARKERS MARKET: IMPACT ANALYSIS
TABLE 2 BIOMARKERS MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 3 BIOMARKERS MARKET: ROLE IN ECOSYSTEM
TABLE 4 AVERAGE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023-2025 (USD)
TABLE 5 INDICATIVE SELLING PRICE OF CONSUMABLES, BY REGION, 2025
TABLE 6 IMPORT DATA FOR HS CODE 382219, 2022-2025, (USD THOUSAND)
TABLE 7 EXPORT DATA HS CODE 382200, 2022-2025, (USD THOUSAND)
TABLE 8 IMPORT VOLUME HS CODE 382219, 2022-2025 (TONS)
TABLE 9 EXPORT VOLUME HS CODE 382219, 2022-2025 (TONS)
TABLE 10 BIOMARKERS MARKET: KEY CONFERENCES & EVENTS, 2026-2027
TABLE 11 CASE STUDY 1: ADVANCED GENOMIC PROFILING TO SUPPORT PRECISION ONCOLOGY ADOPTION
TABLE 12 CASE STUDY 2: EXPANSION OF LIQUID BIOPSY ACCESS FOR MINIMALLY INVASIVE CANCER BIOMARKER TESTING
TABLE 13 CASE STUDY 3: POPULATION PROTEOMICS EXPANSION TO ACCELERATE BIOMARKER DISCOVERY
TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 15 INDICATIVE LIST OF PATENTS IN BIOMARKERS MARKET, 2025
TABLE 16 CASE STUDIES OF AI IMPLEMENTATION IN BIOMARKERS MARKET
TABLE 17 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN BIOMARKERS MARKET
TABLE 18 KEY SUCCESS STORIES WITH RESPECT TO REAL-WORLD APPLICATIONS IN BIOMARKERS MARKET
TABLE 19 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 COUNTRY-WISE REGULATORY SCENARIO FOR BIOMARKER-BASED PRODUCT & SERVICE PROVIDERS
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%)
TABLE 25 KEY BUYING CRITERIA, BY END USER
TABLE 26 BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 27 BIOMARKER CONSUMABLES MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 28 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 29 EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 30 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 31 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 32 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 33 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 34 BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 35 BIOMARKER ASSAY KITS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 36 NORTH AMERICA: BIOMARKER ASSAY KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 37 EUROPE: BIOMARKER ASSAY KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 38 ASIA PACIFIC: BIOMARKER ASSAY KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 39 LATIN AMERICA: BIOMARKER ASSAY KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 40 MIDDLE EAST: BIOMARKER ASSAY KITS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 41 GCC COUNTRIES: BIOMARKER ASSAY KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 42 BIOMARKER REAGENTS & CHEMICALS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 43 NORTH AMERICA: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 44 EUROPE: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 45 ASIA PACIFIC: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 46 LATIN AMERICA: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 47 MIDDLE EAST: BIOMARKER REAGENTS & CHEMICALS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 48 GCC COUNTRIES: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 49 OTHER BIOMARKER CONSUMABLES MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 50 NORTH AMERICA: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 51 EUROPE: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 52 ASIA PACIFIC: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 53 LATIN AMERICA: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 54 MIDDLE EAST: OTHER BIOMARKER CONSUMABLES MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 55 GCC COUNTRIES: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 56 BIOMARKER SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 57 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 58 EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 59 ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 60 LATIN AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 61 MIDDLE EAST: BIOMARKER SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 62 GCC COUNTRIES: BIOMARKER SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 63 BIOMARKER SOFTWARE MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 64 NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 65 EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 66 ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 67 LATIN AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 68 MIDDLE EAST: BIOMARKER SOFTWARE MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 69 GCC COUNTRIES: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 70 BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 71 SAFETY BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 72 NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 73 EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 74 ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 75 LATIN AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 76 MIDDLE EAST: SAFETY BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 77 GCC COUNTRIES: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 78 EFFICACY BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 79 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 80 EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 81 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 82 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 83 MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 84 GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 85 EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 86 PREDICTIVE BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 87 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 88 EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 89 ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 90 LATIN AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 91 MIDDLE EAST: PREDICTIVE BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 92 GCC COUNTRIES: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 93 SURROGATE BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 94 NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 95 EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 96 ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 97 LATIN AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 98 MIDDLE EAST: SURROGATE BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 99 GCC COUNTRIES: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 100 PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 101 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 102 EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 103 ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 104 LATIN AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 105 MIDDLE EAST: PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 106 GCC COUNTRIES: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 107 PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 108 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 109 EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 110 ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 111 LATIN AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 112 MIDDLE EAST: PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 113 GCC COUNTRIES: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 114 VALIDATION BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 115 NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 116 EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 117 ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 118 LATIN AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 119 MIDDLE EAST: VALIDATION BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 120 GCC COUNTRIES: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 121 BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 122 BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2024-2031 (USD MILLION)
TABLE 123 NORTH AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 124 EUROPE: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 125 ASIA PACIFIC: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 126 LATIN AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 127 MIDDLE EAST: BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2024-2031 (USD MILLION)
TABLE 128 GCC COUNTRIES: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 129 BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2024-2031 (USD MILLION)
TABLE 130 NORTH AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 131 EUROPE: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 132 ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 133 LATIN AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 134 MIDDLE EAST: BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2024-2031 (USD MILLION)
TABLE 135 GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 136 BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2024-2031 (USD MILLION)
TABLE 137 NORTH AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 138 EUROPE: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 139 ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 140 LATIN AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 141 MIDDLE EAST: BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2024-2031 (USD MILLION)
TABLE 142 GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 143 BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2024-2031 (USD MILLION)
TABLE 144 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 145 EUROPE: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 146 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 147 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 148 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2024-2031 (USD MILLION)
TABLE 149 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 150 BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031(USD MILLION)
TABLE 151 BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2024-2031(USD MILLION)
TABLE 152 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 153 EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 154 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 155 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 156 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2024-2031(USD MILLION)
TABLE 157 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 158 BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031(USD MILLION)
TABLE 159 BIOMARKERS MARKET FOR ELISA, BY REGION, 2024-2031(USD MILLION)
TABLE 160 NORTH AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 161 EUROPE: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 162 ASIA PACIFIC: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 163 LATIN AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 164 MIDDLE EAST: BIOMARKERS MARKET FOR ELISA, BY REGION, 2024-2031(USD MILLION)
TABLE 165 GCC COUNTRIES: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 166 BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY REGION, 2024-2031(USD MILLION)
TABLE 167 NORTH AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 168 EUROPE: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 169 ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 170 LATIN AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 171 MIDDLE EAST: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY REGION, 2024-2031(USD MILLION)
TABLE 172 GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 173 BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION, 2024-2031(USD MILLION)
TABLE 174 NORTH AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 175 EUROPE: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 176 ASIA PACIFIC: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 177 LATIN AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 178 MIDDLE EAST: BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION, 2024-2031(USD MILLION)
TABLE 179 GCC COUNTRIES: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 180 BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024-2031(USD MILLION)
TABLE 181 NORTH AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 182 EUROPE: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 183 ASIA PACIFIC: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 184 LATIN AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 185 MIDDLE EAST: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024-2031(USD MILLION)
TABLE 186 GCC COUNTRIES: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, 2024-2031(USD MILLION)
TABLE 187 BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2024-2031(USD MILLION)
TABLE 188 NORTH AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 189 EUROPE: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 190 ASIA PACIFIC: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 191 LATIN AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 192 MIDDLE EAST: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2024-2031(USD MILLION)
TABLE 193 GCC COUNTRIES: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 194 BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024-2031(USD MILLION)
TABLE 195 NORTH AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 196 EUROPE: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 197 ASIA PACIFIC: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 198 LATIN AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 199 MIDDLE EAST: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024-2031(USD MILLION)
TABLE 200 GCC COUNTRIES: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 201 BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY REGION, 2024-2031(USD MILLION)
TABLE 202 NORTH AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 203 EUROPE: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 204 ASIA PACIFIC: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 205 LATIN AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 206 MIDDLE EAST: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY REGION, 2024-2031(USD MILLION)
TABLE 207 GCC COUNTRIES: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 208 BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024-2031(USD MILLION)
TABLE 209 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 210 EUROPE: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 211 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 212 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 213 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024-2031(USD MILLION)
TABLE 214 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031(USD MILLION)
TABLE 215 BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 216 BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024-2031 (USD MILLION)
TABLE 217 NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 218 EUROPE: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 219 ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 220 LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 221 MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024-2031 (USD MILLION)
TABLE 222 GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 223 BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
TABLE 224 NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 225 EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 226 ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 227 LATIN AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 228 MIDDLE EAST: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
TABLE 229 GCC COUNTRIES: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 230 LIST OF KEY PERSONALIZED MEDICINE AND RELEVANT BIOMARKERS
TABLE 231 BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2024-2031 (USD MILLION)
TABLE 232 NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 233 EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 234 ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 235 LATIN AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 236 MIDDLE EAST: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2024-2031 (USD MILLION)
TABLE 237 GCC COUNTRIES: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 238 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES, BY LOCATION
TABLE 239 BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2024-2031 (USD MILLION)
TABLE 240 NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 241 EUROPE: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 242 ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 243 LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 244 MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2024-2031 (USD MILLION)
TABLE 245 GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 246 BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 247 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 248 EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 249 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 250 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 251 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 252 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 253 BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 254 LIST OF FDA-APPROVED BIOMARKERS FOR CANCER, BY TYPE
TABLE 255 BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 256 BIOMARKERS MARKET FOR CANCER, BY REGION, 2024-2031 (USD MILLION)
TABLE 257 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 258 EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 259 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 260 LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 261 MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY REGION, 2024-2031 (USD MILLION)
TABLE 262 GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 263 BIOMARKERS MARKET FOR BREAST CANCER, BY REGION, 2024-2031 (USD MILLION)
TABLE 264 NORTH AMERICA: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 265 EUROPE: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 266 ASIA PACIFIC: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 267 LATIN AMERICA: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 268 MIDDLE EAST: BIOMARKERS MARKET FOR BREAST CANCER, BY REGION, 2024-2031 (USD MILLION)
TABLE 269 GCC COUNTRIES: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 270 BIOMARKERS MARKET FOR LUNG CANCER, BY REGION, 2024-2031 (USD MILLION)
TABLE 271 NORTH AMERICA: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 272 EUROPE: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 273 ASIA PACIFIC: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 274 LATIN AMERICA: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 275 MIDDLE EAST: BIOMARKERS MARKET FOR LUNG CANCER, BY REGION, 2024-2031 (USD MILLION)
TABLE 276 GCC COUNTRIES: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 277 BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION, 2024-2031 (USD MILLION)
TABLE 278 NORTH AMERICA: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 279 EUROPE: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 280 ASIA PACIFIC: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 281 LATIN AMERICA: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 282 MIDDLE EAST: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION, 2024-2031 (USD MILLION)
TABLE 283 GCC COUNTRIES: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 284 BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION, 2024-2031 (USD MILLION)
TABLE 285 NORTH AMERICA: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 286 EUROPE: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 287 ASIA PACIFIC: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 288 LATIN AMERICA: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 289 MIDDLE EAST: BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION, 2024-2031 (USD MILLION)
TABLE 290 GCC COUNTRIES: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 291 BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY REGION, 2024-2031 (USD MILLION)
TABLE 292 NORTH AMERICA: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 293 EUROPE: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 294 ASIA PACIFIC: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 295 LATIN AMERICA: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 296 MIDDLE EAST: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY REGION, 2024-2031 (USD MILLION)
TABLE 297 GCC COUNTRIES: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 298 BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 299 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 300 EUROPE: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 301 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 302 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 303 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 304 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 305 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 306 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
TABLE 307 NORTH AMERICA: INFECTIOUS DISEASES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 308 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 309 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 310 LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 311 MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
TABLE 312 GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 313 BIOMARKERS MARKET FOR HIV/AIDS, BY REGION, 2024-2031 (USD MILLION)
TABLE 314 NORTH AMERICA: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 315 EUROPE: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 316 ASIA PACIFIC: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 317 LATIN AMERICA: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 318 MIDDLE EAST: BIOMARKERS MARKET FOR HIV/AIDS, BY REGION, 2024-2031 (USD MILLION)
TABLE 319 GCC COUNTRIES: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 320 BIOMARKERS MARKET FOR HEPATITIS (B & C), BY REGION, 2024-2031 (USD MILLION)
TABLE 321 NORTH AMERICA: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 322 EUROPE: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 323 ASIA PACIFIC: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 324 LATIN AMERICA: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 325 MIDDLE EAST: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY REGION, 2024-2031 (USD MILLION)
TABLE 326 GCC COUNTRIES: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 327 BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 328 NORTH AMERICA: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 329 EUROPE: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 330 ASIA PACIFIC: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 331 LATIN AMERICA: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 332 MIDDLE EAST: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 333 GCC COUNTRIES: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 334 BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
TABLE 335 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 336 EUROPE: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 337 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 338 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 339 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
TABLE 340 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 341 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS
TABLE 342 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 343 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 344 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 345 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 346 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 347 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 348 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 349 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 350 BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2024-2031 (USD MILLION)
TABLE 351 NORTH AMERICA: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 352 EUROPE: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 353 ASIA PACIFIC: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 354 LATIN AMERICA: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 355 MIDDLE EAST: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2024-2031 (USD MILLION)
TABLE 356 GCC COUNTRIES: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 357 BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY REGION, 2024-2031 (USD MILLION)
TABLE 358 NORTH AMERICA: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 359 EUROPE: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 360 ASIA PACIFIC: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 361 LATIN AMERICA: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 362 MIDDLE EAST: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY REGION, 2024-2031 (USD MILLION)
TABLE 363 GCC COUNTRIES: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 364 BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 365 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 366 EUROPE: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 367 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 368 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 369 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 370 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 371 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 372 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 373 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 374 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 375 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 376 LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 377 MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 378 GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 379 BIOMARKERS MARKET FOR ALZHEIMER'S DISEASE, BY REGION, 2024-2031 (USD MILLION)
TABLE 380 NORTH AMERICA: BIOMARKERS MARKET FOR ALZHEIMER'S DISEASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 381 EUROPE: BIOMARKERS MARKET FOR ALZHEIMER'S DISEASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 382 ASIA PACIFIC: BIOMARKERS MARKET FOR ALZHEIMER'S DISEASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 383 LATIN AMERICA: BIOMARKERS MARKET FOR ALZHEIMER'S DISEASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 384 MIDDLE EAST: BIOMARKERS MARKET FOR ALZHEIMER'S DISEASE, BY REGION, 2024-2031 (USD MILLION)
TABLE 385 GCC COUNTRIES: BIOMARKERS MARKET FOR ALZHEIMER'S DISEASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 386 BIOMARKERS MARKET FOR PARKINSON'S DISEASE, BY REGION, 2024-2031 (USD MILLION)
TABLE 387 NORTH AMERICA: BIOMARKERS MARKET FOR PARKINSON'S DISEASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 388 EUROPE: BIOMARKERS MARKET FOR PARKINSON'S DISEASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 389 ASIA PACIFIC: BIOMARKERS MARKET FOR PARKINSON'S DISEASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 390 LATIN AMERICA: BIOMARKERS MARKET FOR PARKINSON'S DISEASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 391 MIDDLE EAST: BIOMARKERS MARKET FOR PARKINSON'S DISEASE, BY REGION, 2024-2031 (USD MILLION)
TABLE 392 GCC COUNTRIES: BIOMARKERS MARKET FOR PARKINSON'S DISEASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 393 BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2024-2031 (USD MILLION)
TABLE 394 NORTH AMERICA: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 395 EUROPE: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 396 ASIA PACIFIC: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 397 LATIN AMERICA: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 398 MIDDLE EAST: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2024-2031 (USD MILLION)
TABLE 399 GCC COUNTRIES: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 400 BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 401 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 402 EUROPE: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 403 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 404 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 405 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 406 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 407 BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 408 BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 409 NORTH AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 410 EUROPE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 411 ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 412 LATIN AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 413 MIDDLE EAST: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 414 GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 415 BIOMARKERS MARKET FOR DIABETES, BY REGION, 2024-2031 (USD MILLION)
TABLE 416 NORTH AMERICA: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 417 EUROPE: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 418 ASIA PACIFIC: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 419 LATIN AMERICA: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 420 MIDDLE EAST: BIOMARKERS MARKET FOR DIABETES, BY REGION, 2024-2031 (USD MILLION)
TABLE 421 GCC COUNTRIES: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 422 BIOMARKERS MARKET FOR OBESITY, BY REGION, 2024-2031 (USD MILLION)
TABLE 423 NORTH AMERICA: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 424 EUROPE: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 425 ASIA PACIFIC: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 426 LATIN AMERICA: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 427 MIDDLE EAST: BIOMARKERS MARKET FOR OBESITY, BY REGION, 2024-2031 (USD MILLION)
TABLE 428 GCC COUNTRIES: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 429 BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 430 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 431 EUROPE: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 432 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 433 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 434 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 435 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 436 BIOMARKERS FOR CARDIOVASCULAR DISORDERS
TABLE 437 BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 438 NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 439 EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 440 ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 441 LATIN AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 442 MIDDLE EAST: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 443 GCC COUNTRIES: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 444 BIOMARKERS FOR RENAL DISORDERS
TABLE 445 BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 446 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 447 EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 448 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 449 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 450 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 451 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 452 BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 453 BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 454 NORTH AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 455 EUROPE: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 456 ASIA PACIFIC: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 457 LATIN AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 458 MIDDLE EAST: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 459 GCC COUNTRIES: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 460 BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 461 NORTH AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 462 EUROPE: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 463 ASIA PACIFIC: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 464 LATIN AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 465 MIDDLE EAST: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 466 GCC COUNTRIES: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 467 BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
TABLE 468 NORTH AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 469 EUROPE: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 470 ASIA PACIFIC: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 471 LATIN AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 472 MIDDLE EAST: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
TABLE 473 GCC COUNTRIES: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 474 BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 475 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 476 EUROPE: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 477 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 478 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 479 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
TABLE 480 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 481 BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 482 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 483 NORTH AMERICA: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 484 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 485 NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 486 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 487 NORTH AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 488 NORTH AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 489 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 490 NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 491 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 492 NORTH AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 493 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 494 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 495 NORTH AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 496 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 497 NORTH AMERICA: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 498 US: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 499 US: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 500 US: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 501 US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 502 US: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 503 US: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 504 US: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 505 US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 506 US: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 507 US: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 508 US: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 509 US: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 510 US: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 511 US: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 512 US: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 513 CANADA: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 514 CANADA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 515 CANADA: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 516 CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 517 CANADA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 518 CANADA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 519 CANADA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 520 CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 521 CANADA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 522 CANADA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 523 CANADA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 524 CANADA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 525 CANADA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 526 CANADA: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 527 CANADA: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 528 EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 529 EUROPE: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 530 EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 531 EUROPE: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 532 EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 533 EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 534 EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 535 EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 536 EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 537 EUROPE: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 538 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 539 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 540 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 541 EUROPE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 542 EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 543 EUROPE: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 544 GERMANY: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 545 GERMANY: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 546 GERMANY: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 547 GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 548 GERMANY: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 549 GERMANY: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 550 GERMANY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 551 GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 552 GERMANY: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 553 GERMANY: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 554 GERMANY: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 555 GERMANY: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 556 GERMANY: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 557 GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 558 GERMANY: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 559 UK: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 560 UK: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 561 UK: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 562 UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 563 UK: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 564 UK: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 565 UK: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 566 UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 567 UK: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 568 UK: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 569 UK: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 570 UK: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 571 UK: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 572 UK: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 573 UK: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 574 FRANCE: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 575 FRANCE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 576 FRANCE: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 577 FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 578 FRANCE: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 579 FRANCE: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 580 FRANCE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 581 FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 582 FRANCE: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 583 FRANCE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 584 FRANCE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 585 FRANCE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 586 FRANCE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 587 FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 588 FRANCE: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 589 ITALY: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 590 ITALY: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 591 ITALY: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 592 ITALY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 593 ITALY: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 594 ITALY: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 595 ITALY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 596 ITALY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 597 ITALY: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 598 ITALY: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 599 ITALY: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 600 ITALY: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 601 ITALY: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 602 ITALY: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 603 ITALY: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 604 SPAIN: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 605 SPAIN: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 606 SPAIN: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 607 SPAIN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 608 SPAIN: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 609 SPAIN: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 610 SPAIN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 611 SPAIN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 612 SPAIN: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 613 SPAIN: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 614 SPAIN: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 615 SPAIN: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 616 SPAIN: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 617 SPAIN: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 618 SPAIN: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 619 REST OF EUROPE: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 620 REST OF EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 621 REST OF EUROPE: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 622 REST OF EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 623 REST OF EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 624 REST OF EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 625 REST OF EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 626 REST OF EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 627 REST OF EUROPE: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 628 REST OF EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 629 REST OF EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 630 REST OF EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 631 REST OF EUROPE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 632 REST OF EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 633 REST OF EUROPE: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 634 ASIA PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 635 ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 636 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 637 ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 638 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 639 ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 640 ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 641 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 642 ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 643 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 644 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 645 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 646 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 647 ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 648 ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 649 ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 650 CHINA: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 651 CHINA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 652 CHINA: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 653 CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 654 CHINA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 655 CHINA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 656 CHINA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 657 CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 658 CHINA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 659 CHINA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 660 CHINA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 661 CHINA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 662 CHINA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 663 CHINA: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 664 CHINA: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 665 JAPAN: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 666 JAPAN: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 667 JAPAN: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 668 JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 669 JAPAN: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 670 JAPAN: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 671 JAPAN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 672 JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 673 JAPAN: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 674 JAPAN: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 675 JAPAN: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 676 JAPAN: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 677 JAPAN: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 678 JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 679 JAPAN: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 680 INDIA: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 681 INDIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 682 INDIA: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 683 INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 684 INDIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 685 INDIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 686 INDIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 687 INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 688 INDIA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 689 INDIA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 690 INDIA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 691 INDIA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 692 INDIA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 693 INDIA: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 694 INDIA: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 695 SOUTH KOREA: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 696 SOUTH KOREA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 697 SOUTH KOREA: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 698 SOUTH KOREA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 699 SOUTH KOREA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 700 SOUTH KOREA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 701 SOUTH KOREA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 702 SOUTH KOREA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 703 SOUTH KOREA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 704 SOUTH KOREA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 705 SOUTH KOREA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 706 SOUTH KOREA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 707 SOUTH KOREA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 708 SOUTH KOREA: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 709 SOUTH KOREA: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 710 AUSTRALIA: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 711 AUSTRALIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 712 AUSTRALIA: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 713 AUSTRALIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 714 AUSTRALIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 715 AUSTRALIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 716 AUSTRALIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 717 AUSTRALIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 718 AUSTRALIA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 719 AUSTRALIA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 720 AUSTRALIA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 721 AUSTRALIA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 722 AUSTRALIA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 723 AUSTRALIA: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 724 AUSTRALIA: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 725 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 726 REST OF ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 727 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 728 REST OF ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 729 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 730 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 731 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 732 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 733 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 734 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 735 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 736 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 737 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 738 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 739 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 740 LATIN AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 741 LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 742 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 743 LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 744 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 745 LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 746 LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 747 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 748 LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 749 LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 750 LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 751 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 752 LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 753 LATIN AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 754 LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 755 LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 756 BRAZIL: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 757 BRAZIL: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 758 BRAZIL: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 759 BRAZIL: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 760 BRAZIL: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 761 BRAZIL: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 762 BRAZIL: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 763 BRAZIL: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 764 BRAZIL: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 765 BRAZIL: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 766 BRAZIL: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 767 BRAZIL: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 768 BRAZIL: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 769 BRAZIL: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 770 BRAZIL: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 771 MEXICO: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 772 MEXICO: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 773 MEXICO: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 774 MEXICO: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 775 MEXICO: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 776 MEXICO: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 777 MEXICO: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 778 MEXICO: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 779 MEXICO: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 780 MEXICO: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 781 MEXICO: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 782 MEXICO: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 783 MEXICO: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 784 MEXICO: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 785 MEXICO: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 786 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 787 REST OF LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 788 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 789 REST OF LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 790 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 791 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 792 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 793 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 794 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 795 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 796 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 797 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 798 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 799 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 800 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 801 MIDDLE EAST: BIOMARKERS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 802 MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 803 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 804 MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 805 MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 806 MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 807 MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 808 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 809 MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 810 MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 811 MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 812 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 813 MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 814 MIDDLE EAST: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 815 MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 816 MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 817 GCC COUNTRIES: BIOMARKERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 818 GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 819 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 820 GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 821 GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 822 GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 823 GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 824 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 825 GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 826 GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 827 GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 828 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 829 GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 830 GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 831 GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 832 GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 833 SAUDI ARABIA: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 834 SAUDI ARABIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 835 SAUDI ARABIA: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 836 SAUDI ARABIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 837 SAUDI ARABIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 838 SAUDI ARABIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 839 SAUDI ARABIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 840 SAUDI ARABIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 841 SAUDI ARABIA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 842 SAUDI ARABIA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 843 SAUDI ARABIA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 844 SAUDI ARABIA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 845 SAUDI ARABIA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 846 SAUDI ARABIA: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 847 SAUDI ARABIA: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 848 UAE: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 849 UAE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 850 UAE: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 851 UAE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 852 UAE: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 853 UAE: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 854 UAE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 855 UAE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 856 UAE: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 857 UAE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 858 UAE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 859 UAE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 860 UAE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 861 UAE: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 862 UAE: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 863 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 864 REST OF GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 865 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 866 REST OF GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 867 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 868 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 869 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 870 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 871 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 872 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 873 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 874 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 875 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 876 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 877 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 878 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 879 REST OF MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 880 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 881 REST OF MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 882 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 883 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 884 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 885 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 886 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 887 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 888 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 889 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 890 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 891 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 892 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 893 AFRICA: BIOMARKERS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 894 AFRICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 895 AFRICA: BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 896 AFRICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 897 AFRICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024-2031 (USD MILLION)
TABLE 898 AFRICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 899 AFRICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 900 AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024-2031 (USD MILLION)
TABLE 901 AFRICA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
TABLE 902 AFRICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 903 AFRICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 904 AFRICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 905 AFRICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 906 AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 907 AFRICA: BIOMARKERS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 908 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN BIOMARKERS MARKET
TABLE 909 BIOMARKERS MARKET: DEGREE OF COMPETITION
TABLE 910 BIOMARKERS MARKET: REGION FOOTPRINT
TABLE 911 BIOMARKERS MARKET: OFFERING FOOTPRINT
TABLE 912 BIOMARKERS MARKET: TECHNOLOGY FOOTPRINT
TABLE 913 BIOMARKERS MARKET: APPLICATION FOOTPRINT
TABLE 914 BIOMARKERS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
TABLE 915 BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES PLAYERS
TABLE 916 BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JUNE 2026
TABLE 917 BIOMARKERS MARKET: DEALS, JANUARY 2023-JUNE 2026
TABLE 918 BIOMARKERS MARKET: EXPANSIONS, JANUARY 2023-JUNE 2026
TABLE 919 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
TABLE 920 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED
TABLE 921 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JUNE 2026
TABLE 922 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023-JUNE 2026
TABLE 923 DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 924 DANAHER CORPORATION: PRODUCTS OFFERED
TABLE 925 ILLUMINA, INC.: BUSINESS OVERVIEW
TABLE 926 ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED
TABLE 927 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JUNE 2026
TABLE 928 ILLUMINA, INC.: DEALS, JANUARY 2023-JUNE 2026
TABLE 929 MERCK KGAA: BUSINESS OVERVIEW
TABLE 930 MERCK KGAA: PRODUCTS & SERVICES OFFERED
TABLE 931 MERCK KGAA: DEALS, JANUARY 2023-JUNE 2026
TABLE 932 MERCK KGAA: EXPANSIONS, JANUARY 2023-JUNE 2026
TABLE 933 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
TABLE 934 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
TABLE 935 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS, JANUARY 2023-JUNE 2026
TABLE 936 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023-JUNE 2026
TABLE 937 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023-JUNE 2026
TABLE 938 QIAGEN: BUSINESS OVERVIEW
TABLE 939 QIAGEN: PRODUCTS & SERVICES OFFERED
TABLE 940 QIAGEN: PRODUCT LAUNCHES, JANUARY 2023-JUNE 2026
TABLE 941 QIAGEN: DEALS, JANUARY 2023-JUNE 2026
TABLE 942 QIAGEN: EXPANSIONS, JANUARY 2023-JUNE 2026
TABLE 943 ABBOTT: BUSINESS OVERVIEW
TABLE 944 ABBOTT: PRODUCTS & SERVICES OFFERED
TABLE 945 ABBOTT: PRODUCT APPROVALS, JANUARY 2023-JUNE 2026
TABLE 946 ABBOTT: DEALS, JANUARY 2023-JUNE 2026
TABLE 947 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
TABLE 948 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
TABLE 949 AGILENT TECHNOLOGIES, INC.: PRODUCT APPROVALS, JANUARY 2023-JUNE 2026
TABLE 950 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023-JUNE 2026
TABLE 951 REVVITY INC.: BUSINESS OVERVIEW
TABLE 952 REVVITY INC.: PRODUCTS & SERVICES OFFERED
TABLE 953 REVVITY INC.: PRODUCT LAUNCHES, JANUARY 2023-JUNE 2026
TABLE 954 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
TABLE 955 CHARLES RIVER LABORATORIES: PRODUCTS & SERVICES OFFERED
TABLE 956 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2023-JUNE 2026
TABLE 957 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
TABLE 958 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
TABLE 959 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2023-JUNE 2026
TABLE 960 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023-JUNE 2026
TABLE 961 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
TABLE 962 EUROFINS SCIENTIFIC: PRODUCTS & SERVICES OFFERED
TABLE 963 EUROFINS SCIENTIFIC: DEALS, JANUARY 2023-JUNE 2026
TABLE 964 BIOMERIEUX: BUSINESS OVERVIEW
TABLE 965 BIOMERIEUX: PRODUCTS & SERVICES OFFERED
TABLE 966 BIOMERIEUX: PRODUCT APPROVALS, JANUARY 2023-JUNE 2026
TABLE 967 BIOMERIEUX: DEALS, JANUARY 2023-JUNE 2026
TABLE 968 BIOMERIEUX: EXPANSIONS, JANUARY 2023-JUNE 2026
TABLE 969 JSR CORPORATION: BUSINESS OVERVIEW
TABLE 970 JSR CORPORATION: PRODUCTS & SERVICES OFFERED
TABLE 971 JSR CORPORATION: DEALS, JANUARY 2023-JUNE 2026
TABLE 972 GUARDANT HEALTH: BUSINESS OVERVIEW
TABLE 973 GUARDANT HEALTH: PRODUCTS & SERVICES OFFERED
TABLE 974 GUARDANT HEALTH: PRODUCT APPROVALS, JANUARY 2023-JUNE 2026
TABLE 975 GUARDANT HEALTH: DEALS, JANUARY 2023-JUNE 2026
TABLE 976 LABCORP: BUSINESS OVERVIEW
TABLE 977 LABCORP: PRODUCTS & SERVICES OFFERED
TABLE 978 LABCORP: PRODUCT LAUNCHES, JANUARY 2023-JUNE 2026
TABLE 979 LABCORP: DEALS, JANUARY 2023-JUNE 2026
TABLE 980 QUANTERIX: BUSINESS OVERVIEW
TABLE 981 QUANTERIX: PRODUCTS & SERVICES OFFERED
TABLE 982 QUANTERIX: PRODUCT LAUNCHES, JANUARY 2023-JUNE 2026
TABLE 983 QUANTERIX: DEALS, JANUARY 2023-JUNE 2026
TABLE 984 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW
TABLE 985 MESO SCALE DIAGNOSTICS, LLC: PRODUCTS & SERVICES OFFERED
TABLE 986 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
TABLE 987 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
TABLE 988 CELERION: COMPANY OVERVIEW
TABLE 989 STANDARD BIOTOOLS: COMPANY OVERVIEW
TABLE 990 SEBIA: COMPANY OVERVIEW
TABLE 991 BIOAGILYTIX LABS: COMPANY OVERVIEW
TABLE 992 STRESSMARQ BIOSCIENCES INC.: COMPANY OVERVIEW
TABLE 993 NORTHEAST BIOANALYTICAL LABORATORIES LLC: BUSINESS OVERVIEW
TABLE 994 SIGNOSIS: BUSINESS OVERVIEW
TABLE 995 SERIMMUNE: BUSINESS OVERVIEW
TABLE 996 THERAINDX LIFESCIENCES PVT. LTD.: BUSINESS OVERVIEW
TABLE 997 SYNEXA LIFE SCIENCES BV: BUSINESS OVERVIEW
TABLE 998 DIATECH PHARMACOGENETICS: BUSINESS OVERVIEW
TABLE 999 PILLAR BIOSCIENCES: BUSINESS OVERVIEW
TABLE 1000 R-BIOPHARM AG: BUSINESS OVERVIEW

List of Figures

FIGURE 1 BIOMARKERS MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 BIOMARKERS MARKET: YEARS CONSIDERED
FIGURE 3 MARKET SCENARIO
FIGURE 4 GLOBAL BIOMARKERS MARKET, 2024-2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET, 2023-2026
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF BIOMARKERS MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS IN BIOMARKERS MARKET, 2026-2031
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN BIOMARKERS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 9 RISING ADOPTION OF PRECISION MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE MARKET GROWTH
FIGURE 10 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025
FIGURE 11 CONSUMABLES TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 12 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 13 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14 BIOMARKERS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 15 BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 16 BIOMARKERS MARKET: VALUE CHAIN ANALYSIS
FIGURE 17 BIOMARKERS MARKET: ECOSYSTEM ANALYSIS
FIGURE 18 AVERAGE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023-2025 (USD)
FIGURE 19 INDICATIVE SELLING PRICE OF CONSUMABLES, BY REGION, 2025
FIGURE 20 BIOMARKERS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 21 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
FIGURE 22 TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOMARKER PATENTS, 2015-2025
FIGURE 23 IMPACT OF AI/GEN AI ON BIOMARKERS MARKET
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
FIGURE 25 KEY BUYING CRITERIA, BY END USER
FIGURE 26 NORTH AMERICA: BIOMARKERS MARKET SNAPSHOT
FIGURE 27 ASIA PACIFIC: BIOMARKERS MARKET SNAPSHOT
FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN BIOMARKERS MARKET, 2023-2025 (USD MILLION)
FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOMARKERS MARKET (2025)
FIGURE 30 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 31 BIOMARKERS MARKET: COMPANY FOOTPRINT
FIGURE 32 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 33 EV/EBITDA OF KEY VENDORS
FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 35 BIOMARKERS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025)
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 38 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 40 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 41 QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 42 ABBOTT: COMPANY SNAPSHOT (2025)
FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 44 REVVITY INC.: COMPANY SNAPSHOT (2025)
FIGURE 45 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2025)
FIGURE 46 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 47 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
FIGURE 48 BIOMERIEUX: COMPANY SNAPSHOT (2025)
FIGURE 49 JSR CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 50 GUARDANT HEALTH: COMPANY SNAPSHOT (2025)
FIGURE 51 LABCORP: COMPANY SNAPSHOT (2025)
FIGURE 52 QUANTERIX: COMPANY SNAPSHOT (2025)
FIGURE 53 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT, 2025
FIGURE 54 RESEARCH DESIGN
FIGURE 55 BIOMARKERS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 56 BIOMARKERS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
FIGURE 57 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
FIGURE 58 ILLUSTRATIVE EXAMPLE OF HOFFMANN-LA ROCHE LTD.: REVENUE SHARE ANALYSIS (2025)
FIGURE 59 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 60 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 61 BIOMARKERS MARKET (SUPPLY SIDE): CAGR PROJECTIONS
FIGURE 62 BIOMARKERS MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS
FIGURE 63 DATA TRIANGULATION METHODOLOGY